| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medical Oncology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, England [T. R. J. E.]; Departments of Oncology [E. D. S., G. O., M. L.] and Pharmacokinetics and Metabolism [M. S. B., E. P.], Farmitalia Carlo Erba, Via Carlo Imbonati, Milan, Italy; and Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, England [R. C. C.]
Aromatase inhibitors are a useful therapeutic option in the management of endocrine-dependent advanced breast cancer. A single-dose administration of exemestane (FCE 24304; 6-methylenandrosta-1,4-diene-3,17-dione), a new irreversible aromatase inhibitor, was investigated in 29 healthy postmenopausal female volunteers. The compound, given at p.o. doses of 0,5, 5, 12.5, 25, 50, 200, 400, and 800 mg (n = 3–4), was found to be a well tolerated, potent, long-lasting, and specific inhibitor of estrogen biosynthesis. The minimal dose which produced the maximum suppression of plasma estrogens was 25 mg, reducing plasma estrone, estradiol, and estrone sulfate to 35, 28, and 39% of basal values, respectively. This maximum suppression, observed at 3 days, persisted for at least 5 days after administration of a single dose. However, there was no interference on cortisol, aldosterone, 17-hydroxyprogesterone, or dehydroepiandrostenedione sulfate plasma levels. Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively. Plasma concentrations declined rapidly and fell under the detection limit (10 ng/ml) at 4 (50 mg) or 24 h (200 and 400 mg). No clinically significant adverse events which could be attributed to the drug were reported. Apart from transient eosinophilia in 3 patients, all biochemical and hematological laboratory parameters were within 1.25-fold of the normal ranges.
1 To whom requests for reprints should be addressed.
Received 3/24/92. Accepted 8/26/92.
This article has been cited by other articles:
|
|
 |
|
  E. Rossi, A. Morabito, E. De Maio, F. Di Rella, G. Esposito, A. Gravina, V. Labonia, G. Landi, F. Nuzzo, C. Pacilio, et al. Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer J. Clin. Oncol., January 10, 2008; 26(2): 264 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Ariazi, A. Leitao, T. I. Oprea, B. Chen, T. Louis, A. M. Bertucci, C. G.N. Sharma, S. D. Gill, H. R. Kim, H. A. Shupp, et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen Mol. Cancer Ther., November 1, 2007; 6(11): 2817 - 2827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. HONG and S. CHEN Aromatase Inhibitors: Structural Features and Biochemical Characterization Ann. N.Y. Acad. Sci., November 1, 2006; 1089(1): 237 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz Aromatase Inhibitors in the Treatment of Breast Cancer Endocr. Rev., May 1, 2005; 26(3): 331 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Tobias Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention Ann. Onc., December 1, 2004; 15(12): 1738 - 1747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Coombes, E. Hall, L. J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S. E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer N. Engl. J. Med., March 11, 2004; 350(11): 1081 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mauras, J. Lima, D. Patel, A. Rini, E. di Salle, A. Kwok, and B. Lippe Pharmacokinetics and Dose Finding of a Potent Aromatase Inhibitor, Aromasin (Exemestane), in Young Males J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5951 - 5956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Mamounas NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions Clin. Med. Res., October 1, 2003; 1(4): 309 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Piccart, L. M. Parker, and K. I. Pritchard Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer Ann. Onc., July 1, 2003; 14(7): 1017 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. U. Buzdar Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Clin. Cancer Res., January 1, 2003; 9(1): 468S - 472S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
